ME03744B - Spojevi 1-tetrahidropiranilkarbonil-2,3- dihidro-1h-indola, namijenjeni liječenju raka - Google Patents
Spojevi 1-tetrahidropiranilkarbonil-2,3- dihidro-1h-indola, namijenjeni liječenju rakaInfo
- Publication number
- ME03744B ME03744B MEP-2020-98A MEP202098A ME03744B ME 03744 B ME03744 B ME 03744B ME P202098 A MEP202098 A ME P202098A ME 03744 B ME03744 B ME 03744B
- Authority
- ME
- Montenegro
- Prior art keywords
- cancer
- compound according
- hydrogen
- dihydro
- fluoro
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 3
- 201000011510 cancer Diseases 0.000 title claims 3
- YQMFDGVJPUGMNU-UHFFFAOYSA-N 2,3-dihydroindol-1-yl(oxan-2-yl)methanone Chemical class O1C(CCCC1)C(=O)N1CCC2=CC=CC=C12 YQMFDGVJPUGMNU-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- NUBWFWVVKLRSHS-OAHLLOKOSA-N 4-fluoro-N-[(1R)-1-[1-(oxane-4-carbonyl)-2,3-dihydroindol-5-yl]ethyl]benzamide Chemical compound FC1=CC=C(C(=O)N[C@H](C)C=2C=C3CCN(C3=CC=2)C(=O)C2CCOCC2)C=C1 NUBWFWVVKLRSHS-OAHLLOKOSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- -1 hydroxy, fluoro, benzyloxy Chemical group 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- CPPKAGUPTKIMNP-UHFFFAOYSA-N cyanogen fluoride Chemical compound FC#N CPPKAGUPTKIMNP-UHFFFAOYSA-N 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Chemical group 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (10)
1. Spoj formule: , naznačen time što: R1a je vodik, metil, etenil, cijano, fluor, klor, fluormetil ili difluormetil; R1b je vodik, fluor ili klor; R1c je vodik, hidroksi, fluor, benziloksi ili hidroksietilamino; R2 je vodik ili metil; R2a je vodik ili metil; i R3a je tetrahidropiranil.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je: .
3. Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je: ,
4. Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je: .
5. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što je kristalni 4-fluor-N-{(1R)-1-[1-(tetrahidro-2H-piran-4-ilkarbonil)-2,3-dihidro-1H-indol-5-il]etil}benzamid.
6. Spoj u skladu s patentnim zahtjevom 5, koji je kristalni 4-fluor-N-{(1R)-1-[1-(tetrahidro-2H-piran-4-ilkarbonil)-2,3-dihidro-1H-indol-5-il]etil}benzamid, naznačen time što ima uzorak difrakcije rendgenskih zraka na prahu (zračenje Cu, λ-1,54060 Ǻ), koji sadrži najmanje jedan maksimum na 17,38°, u kombinaciji s jednim ili više maksimuma koje se bira iz skupine koju čine 12,51°, 15,65°, 16,37°, 17,56°, 21,48° i 25,23° (2θ ± 0,2°).
7. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1-6, uz jedan ili više farmaceutski prihvatljivih pomoćnih tvari, nosača ili razrjeđivača.
8. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što je namijenjen upotrebi u terapiji.
9. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što je namijenjen upotrebi u liječenju raka.
10. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što se rak bira iz skupine koju čine melanom, akutna mijeloidna leukemija, kronična limfocitna leukemija, kolorektalni rak, bubrežnih stanica karcinom, rak dojke, rak pluća, rak jajnika, karcinom jajovoda, primarni peritonealni karcinom, rak vrata maternice, želuca rak, jetre rak, rak gušterače, rak štitnjače, gliom, nehodgkinovski limfom, te Hodgkinov limfom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348457P | 2016-06-10 | 2016-06-10 | |
| PCT/US2017/035097 WO2017213919A1 (en) | 2016-06-10 | 2017-05-31 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer |
| EP17728990.7A EP3468965B1 (en) | 2016-06-10 | 2017-05-31 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03744B true ME03744B (me) | 2021-04-20 |
Family
ID=59031409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2020-98A ME03744B (me) | 2016-06-10 | 2017-05-31 | Spojevi 1-tetrahidropiranilkarbonil-2,3- dihidro-1h-indola, namijenjeni liječenju raka |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US10759786B2 (me) |
| EP (1) | EP3468965B1 (me) |
| JP (1) | JP6632746B2 (me) |
| KR (1) | KR102241258B1 (me) |
| CN (1) | CN109641881B (me) |
| AR (1) | AR108586A1 (me) |
| AU (1) | AU2017277833B2 (me) |
| BR (1) | BR112018072872A2 (me) |
| CA (1) | CA3027035C (me) |
| CL (1) | CL2018003543A1 (me) |
| CO (1) | CO2018013251A2 (me) |
| CR (1) | CR20180579A (me) |
| CY (1) | CY1123660T1 (me) |
| DK (1) | DK3468965T3 (me) |
| DO (1) | DOP2018000278A (me) |
| EA (1) | EA037419B1 (me) |
| EC (1) | ECSP19001734A (me) |
| ES (1) | ES2797981T3 (me) |
| HR (1) | HRP20200769T1 (me) |
| HU (1) | HUE050155T2 (me) |
| IL (1) | IL263497B (me) |
| JO (1) | JOP20170131B1 (me) |
| LT (1) | LT3468965T (me) |
| MA (1) | MA45224B1 (me) |
| MD (1) | MD3468965T2 (me) |
| ME (1) | ME03744B (me) |
| MX (1) | MX382877B (me) |
| MY (1) | MY197462A (me) |
| NZ (1) | NZ748500A (me) |
| PE (1) | PE20190378A1 (me) |
| PH (1) | PH12018502572A1 (me) |
| PL (1) | PL3468965T3 (me) |
| PT (1) | PT3468965T (me) |
| RS (1) | RS60322B1 (me) |
| SG (1) | SG11201809625RA (me) |
| SI (1) | SI3468965T1 (me) |
| TW (1) | TWI671294B (me) |
| UA (1) | UA122526C2 (me) |
| WO (1) | WO2017213919A1 (me) |
| ZA (1) | ZA201807688B (me) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| MX384836B (es) | 2016-03-07 | 2025-03-14 | Enanta Pharm Inc | Agentes antivirales contra la hepatitis b |
| NZ762994A (en) | 2017-08-28 | 2025-11-28 | Enanta Pharm Inc | Hepatitis b antiviral agents |
| WO2019089412A1 (en) * | 2017-11-01 | 2019-05-09 | Merck Sharp & Dohme Corp. | Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| US20210002371A1 (en) * | 2017-12-21 | 2021-01-07 | Brian A. Sherer | Combination of an anti-pd-l1 antibody and ido1 inhibitor for the treatment of cancer |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11992489B2 (en) | 2018-08-17 | 2024-05-28 | Merck Sharp & Dohme Llc | Substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors |
| AR116474A1 (es) | 2018-09-21 | 2021-05-12 | Enanta Pharm Inc | DERIVADOS DEL ÁCIDO 6,7-DIHIDRO-2H-BENZOFURO[2,3-a]QUINOLIZIN-3-CARBOXÍLICO COMO AGENTES ANTIVIRALES PARA EL TRATAMIENTO O PREVENCIÓN DE UNA INFECCIÓN POR HBV |
| EP3877366A4 (en) * | 2018-11-06 | 2022-08-24 | Merck Sharp & Dohme Corp. | NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLAMINE-2,3-DIOXYGENASE INHIBITORS |
| SG11202105007TA (en) | 2018-11-21 | 2021-06-29 | Enanta Pharm Inc | Functionalized heterocycles as antiviral agents |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| CN114105961B (zh) * | 2021-12-10 | 2023-09-12 | 海南梵圣生物科技有限公司 | 一种ido1抑制剂(ly-3381916)制备方法 |
| CN114213310B (zh) * | 2021-12-31 | 2024-02-23 | 中国药科大学 | 吲哚啉化合物及其衍生物、制备方法、药物组合物和应用 |
| WO2025072355A1 (en) * | 2023-09-25 | 2025-04-03 | Biohybrid Solutions Holdings, Inc. | Methods for and compositions of non-peg bioconjugates with ultra-high drug-to-agent ratio |
| WO2025140363A1 (zh) * | 2023-12-27 | 2025-07-03 | 海思科医药集团股份有限公司 | 一种苯基哌啶衍生物的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1615698B1 (en) * | 2003-04-11 | 2010-09-29 | High Point Pharmaceuticals, LLC | New amide derivatives and pharmaceutical use thereof |
| AU2006244068B9 (en) * | 2005-05-10 | 2012-10-25 | Incyte Holdings Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
| US7622495B2 (en) * | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| KR20100124272A (ko) * | 2008-02-07 | 2010-11-26 | 아보트 러보러터리즈 | 양성 알로스테릭 조절제로서의 아미드 유도체 및 이의 사용방법 |
| SG192485A1 (en) * | 2008-07-08 | 2013-08-30 | Incyte Corp | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| NO2694640T3 (me) * | 2011-04-15 | 2018-03-17 | ||
| CN105324362B (zh) * | 2013-03-15 | 2017-05-24 | 百时美施贵宝公司 | Ido抑制剂 |
| CA2944240A1 (en) * | 2014-04-04 | 2015-10-08 | Iomet Pharma Ltd | Indole derivatives as ido/tdo inhibitors |
| UY36391A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| JP7304697B2 (ja) * | 2015-12-23 | 2023-07-07 | ムーンショット ファーマ エルエルシー | 未成熟終止コドンのリードスルーを促進することにより免疫反応を誘発するための方法 |
-
2017
- 2017-05-24 AR ARP170101413A patent/AR108586A1/es not_active Application Discontinuation
- 2017-05-24 JO JOP/2017/0131A patent/JOP20170131B1/ar active
- 2017-05-25 TW TW106117300A patent/TWI671294B/zh not_active IP Right Cessation
- 2017-05-31 PE PE2018003199A patent/PE20190378A1/es unknown
- 2017-05-31 CA CA3027035A patent/CA3027035C/en active Active
- 2017-05-31 MX MX2018015275A patent/MX382877B/es unknown
- 2017-05-31 US US16/307,612 patent/US10759786B2/en active Active
- 2017-05-31 ME MEP-2020-98A patent/ME03744B/me unknown
- 2017-05-31 PL PL17728990T patent/PL3468965T3/pl unknown
- 2017-05-31 SG SG11201809625RA patent/SG11201809625RA/en unknown
- 2017-05-31 CN CN201780035976.4A patent/CN109641881B/zh not_active Expired - Fee Related
- 2017-05-31 ES ES17728990T patent/ES2797981T3/es active Active
- 2017-05-31 DK DK17728990.7T patent/DK3468965T3/da active
- 2017-05-31 UA UAA201811735A patent/UA122526C2/uk unknown
- 2017-05-31 MA MA45224A patent/MA45224B1/fr unknown
- 2017-05-31 MY MYPI2018002369A patent/MY197462A/en unknown
- 2017-05-31 PT PT177289907T patent/PT3468965T/pt unknown
- 2017-05-31 NZ NZ748500A patent/NZ748500A/en not_active IP Right Cessation
- 2017-05-31 CR CR20180579A patent/CR20180579A/es unknown
- 2017-05-31 LT LTEP17728990.7T patent/LT3468965T/lt unknown
- 2017-05-31 US US15/609,115 patent/US9872853B2/en active Active
- 2017-05-31 AU AU2017277833A patent/AU2017277833B2/en not_active Ceased
- 2017-05-31 WO PCT/US2017/035097 patent/WO2017213919A1/en not_active Ceased
- 2017-05-31 EP EP17728990.7A patent/EP3468965B1/en active Active
- 2017-05-31 HR HRP20200769TT patent/HRP20200769T1/hr unknown
- 2017-05-31 RS RS20200623A patent/RS60322B1/sr unknown
- 2017-05-31 HU HUE17728990A patent/HUE050155T2/hu unknown
- 2017-05-31 JP JP2018563823A patent/JP6632746B2/ja not_active Expired - Fee Related
- 2017-05-31 MD MDE20190462T patent/MD3468965T2/ro not_active IP Right Cessation
- 2017-05-31 SI SI201730252T patent/SI3468965T1/sl unknown
- 2017-05-31 KR KR1020187035215A patent/KR102241258B1/ko not_active Expired - Fee Related
- 2017-05-31 EA EA201892479A patent/EA037419B1/ru unknown
- 2017-05-31 BR BR112018072872-1A patent/BR112018072872A2/pt not_active Application Discontinuation
-
2018
- 2018-11-15 ZA ZA2018/07688A patent/ZA201807688B/en unknown
- 2018-12-04 IL IL263497A patent/IL263497B/en active IP Right Grant
- 2018-12-06 CO CONC2018/0013251A patent/CO2018013251A2/es unknown
- 2018-12-06 PH PH12018502572A patent/PH12018502572A1/en unknown
- 2018-12-10 DO DO2018000278A patent/DOP2018000278A/es unknown
- 2018-12-10 CL CL2018003543A patent/CL2018003543A1/es unknown
-
2019
- 2019-01-09 EC ECSENADI20191734A patent/ECSP19001734A/es unknown
-
2020
- 2020-06-05 CY CY20201100508T patent/CY1123660T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03744B (me) | Spojevi 1-tetrahidropiranilkarbonil-2,3- dihidro-1h-indola, namijenjeni liječenju raka | |
| HRP20192209T1 (hr) | Derivati benzofurana, postupci njihove pripreme i njihova uporaba u medicini | |
| HRP20221154T1 (hr) | Supstituirani pirazolo[1,5-a]piridinski spojevi kao inhibitori ret kinaze | |
| MX2018008168A (es) | Inhibidores de antigenos de membrana especificos de la prostata (psma) basados en la urea para imaginologia y terapia. | |
| MX2021001583A (es) | Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso. | |
| HRP20210681T1 (hr) | Kristalne soli (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroizokinolin-2(1h)-il)-2-hidroksipropil)pirimidin-4-karboksamida | |
| WO2014152389A8 (en) | Imaging agent for detection of diseased cells | |
| ME02655B (me) | Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja | |
| WO2017075629A3 (en) | Wee 1 kinase inhibitors and methods of making and using the same | |
| HRP20211392T1 (hr) | INHIBITOR EGFR -a, I NJEGOVA PRIPREMA I PRIMJENA | |
| GEP20237479B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| NZ630205A (en) | Enhancer of zeste homolog 2 inhibitors | |
| HRP20150771T1 (hr) | Spoj za inhibiciju notch signalnog puta | |
| GEP201706678B (en) | Method of treating cancer and bone cancer | |
| FI4011881T3 (fi) | Atr-inhibiittorin kiteisiä muotoja ja niiden käyttö | |
| SI3033344T1 (en) | CHEMISULPHATE SOL 5,10-METHYLENE- (6R) -THETRAHYDROPHOLIC ACID | |
| MX381000B (es) | Cristales de compuesto azabicíclico. | |
| EA201691136A1 (ru) | Производное на основе 1,2-нафтохинона и способ его получения | |
| MX389391B (es) | Uso de la carrimicina y las sales farmacéuticamente aceptables de esta para la preparación de medicamentos para el tratamiento y/o la prevención de tumores. | |
| MX2016002795A (es) | Compuestos de triazolona y usos de los mismos. | |
| MX2018007887A (es) | Formas cristalinas de modulador selectivo del receptor s1p1 y método de preparación del mismo. | |
| PH12021551057A1 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| RU2016141650A (ru) | Амидные соединения | |
| EA201891239A1 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| MX2020008498A (es) | Derivados de sobetirome. |